Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists. 2003

Pier Giovanni Baraldi, and Francesca Fruttarolo, and Mojgan Aghazadeh Tabrizi, and Delia Preti, and Romeo Romagnoli, and Hussein El-Kashef, and Allan Moorman, and Katia Varani, and Stefania Gessi, and Stefania Merighi, and Pier Andrea Borea
Dipartimento di Scienze Farmaceutiche and Dipartimento di Medicina Clinica e Sperimentale-Sezione di Farmacologia, Università di Ferrara, 44100 Ferrara, Italy. pgb@dns.unife.it

In the past few years, our group has been involved in the development of A(2A) and A(3) adenosine receptor antagonists which led to the synthesis of SCH58261 (5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, 61), potent and very selective at the A(2A) receptor subtype, and N(8)-substituted-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines-N(5)-urea or amide (MRE series, b), very selective at the human A(3) adenosine receptor subtype. We now describe a large series of C(9)- and C(2)-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines to represent an extension of structure-activity relationship work on this class of tricyclic compounds. The introduction of a substituent at 9 position of the tricyclic antagonistic structure led to retention of receptor affinity but a loss of selectivity in respect to the lead compounds b, N(8)-substituted-pirazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines-N(5)-urea or -amide. The substitution of the furanyl moiety of compound 61, necessary for receptor binding, with a phenyl or a substituted aromatic ring (compounds 5a-d, 6-8), caused a complete loss of the affinity at all the adenosine receptor subtypes, demonstrating that the furanyl ring is a necessary structural element to guarantee interaction with the adenosine receptor surface. The introduction of an ethoxy group at the ortho position of the aromatic ring to mimic the oxygen of the furan (compound 5c, 5-amino-7-(2-phenylethyl)-2-(2-ethoxyphenyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine) did not enhance affinity. The introduction of the cycloaminomethyl function by Mannich reaction at the 5' position of the furanyl ring of 61 and the C(9)-substituted compound 41 (5-amino-8-methyl-9-methylsulfanyl-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine) resulted in complete water solubility but a loss of receptor affinity. We can conclude that modifications or substitutions at the furanyl ring are not allowed and the introduction of a substituent at the 9-position of the core pyrazolo-triazolo-pyrimidine structure caused a severe loss of selectivity, probably due to an increased steric hindrance of the radical introduced.

UI MeSH Term Description Entries
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Pier Giovanni Baraldi, and Francesca Fruttarolo, and Mojgan Aghazadeh Tabrizi, and Delia Preti, and Romeo Romagnoli, and Hussein El-Kashef, and Allan Moorman, and Katia Varani, and Stefania Gessi, and Stefania Merighi, and Pier Andrea Borea
June 1998, Journal of medicinal chemistry,
Pier Giovanni Baraldi, and Francesca Fruttarolo, and Mojgan Aghazadeh Tabrizi, and Delia Preti, and Romeo Romagnoli, and Hussein El-Kashef, and Allan Moorman, and Katia Varani, and Stefania Gessi, and Stefania Merighi, and Pier Andrea Borea
June 2012, Journal of medicinal chemistry,
Pier Giovanni Baraldi, and Francesca Fruttarolo, and Mojgan Aghazadeh Tabrizi, and Delia Preti, and Romeo Romagnoli, and Hussein El-Kashef, and Allan Moorman, and Katia Varani, and Stefania Gessi, and Stefania Merighi, and Pier Andrea Borea
March 2007, Bioorganic & medicinal chemistry letters,
Pier Giovanni Baraldi, and Francesca Fruttarolo, and Mojgan Aghazadeh Tabrizi, and Delia Preti, and Romeo Romagnoli, and Hussein El-Kashef, and Allan Moorman, and Katia Varani, and Stefania Gessi, and Stefania Merighi, and Pier Andrea Borea
January 2012, Bioorganic & medicinal chemistry,
Pier Giovanni Baraldi, and Francesca Fruttarolo, and Mojgan Aghazadeh Tabrizi, and Delia Preti, and Romeo Romagnoli, and Hussein El-Kashef, and Allan Moorman, and Katia Varani, and Stefania Gessi, and Stefania Merighi, and Pier Andrea Borea
January 2016, Current topics in medicinal chemistry,
Pier Giovanni Baraldi, and Francesca Fruttarolo, and Mojgan Aghazadeh Tabrizi, and Delia Preti, and Romeo Romagnoli, and Hussein El-Kashef, and Allan Moorman, and Katia Varani, and Stefania Gessi, and Stefania Merighi, and Pier Andrea Borea
February 2009, Bioorganic & medicinal chemistry letters,
Pier Giovanni Baraldi, and Francesca Fruttarolo, and Mojgan Aghazadeh Tabrizi, and Delia Preti, and Romeo Romagnoli, and Hussein El-Kashef, and Allan Moorman, and Katia Varani, and Stefania Gessi, and Stefania Merighi, and Pier Andrea Borea
July 2019, MedChemComm,
Pier Giovanni Baraldi, and Francesca Fruttarolo, and Mojgan Aghazadeh Tabrizi, and Delia Preti, and Romeo Romagnoli, and Hussein El-Kashef, and Allan Moorman, and Katia Varani, and Stefania Gessi, and Stefania Merighi, and Pier Andrea Borea
March 1996, Journal of medicinal chemistry,
Pier Giovanni Baraldi, and Francesca Fruttarolo, and Mojgan Aghazadeh Tabrizi, and Delia Preti, and Romeo Romagnoli, and Hussein El-Kashef, and Allan Moorman, and Katia Varani, and Stefania Gessi, and Stefania Merighi, and Pier Andrea Borea
August 2011, Molecules (Basel, Switzerland),
Pier Giovanni Baraldi, and Francesca Fruttarolo, and Mojgan Aghazadeh Tabrizi, and Delia Preti, and Romeo Romagnoli, and Hussein El-Kashef, and Allan Moorman, and Katia Varani, and Stefania Gessi, and Stefania Merighi, and Pier Andrea Borea
February 2002, Journal of medicinal chemistry,
Copied contents to your clipboard!